AdvanDx Gets FDA Nod for Bloodstream Pathogen Test | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics company AdvanDx announced today that it has received clearance from the US Food and Drug Administration for a 90-minute version of its peptide nucleic acid fluorescence in situ hybridization (PNA FISH) test for the bloodstream pathogen Enterococcus faecalis.

AdvanDx secured FDA 510(k) clearance for the test, which is faster than the existing two-and-a-half hour E. faecalis PNA FISH test but appears to have similar sensitivity and specificity, based on clinical validation studies in the US and Europe.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.